EyeD Pharma

EyeD Pharma is a clinical-stage pharmaceutical company based in Seraing, Liège, Belgium, founded in 2012.

The company focuses on developing innovative therapeutic solutions for ophthalmic conditions, particularly glaucoma and dry eye disease. EyeD Pharma utilizes a proprietary technology platform that features sustained-release polymeric micro-implants and inserts, designed to replace traditional daily eye drop regimens. This technology enhances patient compliance and reduces side effects by providing controlled, localized drug delivery. The company's product pipeline includes candidates like TimoD, currently in Phase I clinical trials for glaucoma, and HydraD, which is in pre-clinical development for dry eye disease. EyeD Pharma aims to launch its first implants by 2028, addressing significant unmet medical needs in ophthalmology. With plans for expansion and a new facility in the Sart Tilman Science Park, EyeD Pharma is committed to becoming a leader in ophthalmic sustained-release micro-implants and improving patient outcomes in eye care.